Phenoxybenzamine
From Wikipedia, the free encyclopedia
 |
|
|
Phenoxybenzamine
|
|
| Systematic (IUPAC) name | |
| N-benzyl-N-(2-chloroethyl)-1- phenoxy-propan-2-amine | |
| Identifiers | |
| CAS number | |
| ATC code | C04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H22ClNO |
| Mol. mass | 303.826 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 24 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C (U.S.) |
| Legal status | |
| Routes | Oral |
Phenoxybenzamine (marketed under the trade name Dibenzyline) is a non-specific, irreversible alpha blocker used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer lasting effect compared with other alpha blockers. It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia,[1] although it is currently seldom used for that indication due to unfavourable side effects.
[edit] Pharmacology
Phenoxybenzamine is used as an anti-hypertensive due to its efficacy in reducing the vasoconstriction caused by adrenaline and noradrenaline. Phenoxybenzamine forms a permanent covalent bond with adrenergic receptors. Based on what we know about the structures of these receptors, it likely involves attack by the cysteine at position 3.36 in transmembrane helix 3 to form a stable linkage.[2] Thus, it remains permanently bound to the receptor, preventing adrenaline and noradrenaline from binding. This causes vasodilatation in blood vessels, due to its antagonistic effect at the alpha-1 adrenoceptor found in the walls of blood vessels, resulting in a drop in blood pressure.
It will also affect the postsynaptic alpha 1 and 2 receptors in the nervous system, and so reduce sympathetic activity. This results in further vasodilation, pupil constriction, an increase in GI tract motility and secretions, and glycogen synthesis.
It also has partial agonist/antagonist properties at the serotonin 5-HT2A receptor.
[edit] References
- ^ Caine M, Perlberg S, Meretyk S (1978). "A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction". British journal of urology 50 (7): 551–4. PMID 88984.
- ^ Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamäki A (2001). "Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors". J. Biol. Chem. 276 (33): 31279–84. doi:. PMID 11395517.
- Day, M.D. (1979). Autonomic Pharmacology Experimental and Clinical Aspects. Churchill Livingstone.
- Bullock, S. Galbraith, A. Hunt, B. Manias, E. and Richards, A. (1999). Fundamentals of Pharmacology. Pearson Education Limited publishing as Prentice Hall.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||
